H.Amdt. 23House119th Congress (2025-2027)
An amendment numbered 1 printed in Part A of House Report 119-130 to require all HHS regulations or guidance documentation to use language that is inclusive of all opioid overdose reversal drugs that have been approved by FDA, instead of referring to brand names.
Sponsored by 
Rep. Robert P. Bresnahan, Jr. (R-PA)
Rep. Robert P. Bresnahan, Jr. (R-PA)Submitted June 4, 2025
Legislative Activity
Stay on top of the latest movement without scrolling through every action
Floor
Latest Action
House amendment agreed to: On agreeing to the Bresnahan amendment (A001) Agreed to by voice vote.
June 4, 2025 • 3:08 PM
View full timeline
Floor
House amendment agreed to: On agreeing to the Bresnahan amendment (A001) Agreed to by voice vote.
June 4, 2025 • 3:08 PM
Floor
House Amendment Offered
June 4, 2025 • 3:05 PM
Floor
Amendment (A001) offered by Mr. Bresnahan. (consideration: CR H2453; text: CR H2453)
June 4, 2025 • 3:05 PM
Floor
On agreeing to the Bresnahan amendment (A001) Agreed to by voice vote.
June 4, 2025 • 3:08 PM